Horizon Pharma to pay $800M for rare disease drug developer

SHARE Horizon Pharma to pay $800M for rare disease drug developer
horizonpharmalogo_2.jpg

Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

Horizon Pharma, whose U.S. headquarters is in Deerfield, said Monday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.

Raptor’s portfolio includes Procysbi, which treats a rare metabolic disorder, and Quinsair, approved for managing a chronic pulmonary infection in adult patients with cystic fibrosis.

Ireland-based drug developer Horizon Pharma Plc. will pay $9 in cash for each share of Novato, California-based Raptor Pharmaceutical Corp. and expects to close the deal in the fourth quarter.

Drugmakers in recent years have been shifting more money to developing rare disease treatments, as mass-market drugs lose patent protections.

New York-traded shares of Horizon Pharma rose $1.33, or 7.7 percent, to $18.59 in afternoon trading. Shares of Raptor Pharmaceutical jumped $1.51, or 20.2 percent, to $8.96.

The Latest
The government will not use new, unchecked surveillance powers responsibly. It already habitually abuses Section 702, intended for surveillance of foreigners, to search Americans’ communications.
The company, known for its ice cream stores and milk packaged in glass bottles, recently filed for Chapter 11 bankruptcy.
Figueroa was sentenced to 50 years in prison. The infant, Yovanny Jadiel Lopez, died several weeks later.
The current contract expires this summer. On top of raises for staff, the union wants help for unhoused students and more dual language education.
Ukrainian Prime Minster Denys Shmyhal joined Gov. J.B. Pritzker and Biden special representative Penny Pritzker to tout the importance of American investment in Ukraine — while also stressing the dire need for Congress to approve more U.S. aid.